US$ 21.55
dsip bad sleep (Delta Sleep-Inducing Peptide) Therapy DSIP (Delta Sleep Inducing Peptide):
Description
Wound and Bone Healing: Beyond soft tissue, this peptide aids in bone regeneration and wound healing, ensuring comprehensive recovery from various types of injuries

Duvyzats approval follows that of Sareptas Elevidys, which got the FDAs green light in June 2023, and Santhera Pharmaceuticals Agamree, which was approved in October

Potential Research Applications: Sustained growth hormone release studies Muscle growth, recovery, and anti-aging research models Fat metabolism and body composition investigations Long-acting GHRH analog research For laboratory research only

This finding strongly supports the necessity of RAMP1 and RAMP3 for mediating cagrilintide-induced weight loss through AMY1R and AMY3R signaling [2]
